CompletedPhase 1NCT06265012

Study to Evaluate the Recombinant VSV (rVSV)-Marburg Virus Vaccine Candidate (PHV01) in Healthy Adult Subjects

Studying Marburg hemorrhagic fever

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Public Health Vaccines LLC
Principal Investigator: Joan Fusco, PhD
Public Health Vaccines
Intervention: PHV01(biological)
Enrollment: 36 enrolled
Eligibility: 18-60 years · All sexes
Timeline: 2024 – 2024

Study locations (1)

CenExel RCA, Hollywood, Florida, United States

Collaborators

Biomedical Advanced Research and Development Authority

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06265012 on ClinicalTrials.gov

Other trials for Marburg hemorrhagic fever

Additional recruiting or active studies for the same condition.

ACTIVE NOT RECRUITINGPHASE2NCT06620003
A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Marburg Virus Vaccine in Healthy Adults
Albert B. Sabin Vaccine Institute

See all trials for Marburg hemorrhagic fever →

← Back to all trials